Compass Pathways (NASDAQ:CMPS – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.3629) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 2:00 AM ET.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). On average, analysts expect Compass Pathways to post ($1.26) EPS for the current fiscal year and ($1.87) EPS for the next fiscal year.
Compass Pathways Price Performance
Shares of NASDAQ:CMPS opened at $11.05 on Tuesday. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The business has a fifty day simple moving average of $13.06 and a 200 day simple moving average of $10.29. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -2.39 and a beta of 2.55.
Analyst Ratings Changes
A number of brokerages have commented on CMPS. Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price on the stock in a research note on Wednesday, July 8th. Wolfe Research reaffirmed an “outperform” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. BTIG Research lifted their price target on Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. B. Riley Financial boosted their price target on Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada lowered their price target on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Compass Pathways presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.36.
Get Our Latest Report on Compass Pathways
Compass Pathways Company Profile
Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.
Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.
Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.
Featured Articles
- Five stocks we like better than Compass Pathways
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
